Amyotrophic Lateral Sclerosis, also known as Charcot disease, is a neurodegenerative disease evidenced by gradual paralysis of the muscles involved in voluntary motor function. The clinical hallmark of Amyotrophic Lateral Sclerosis is the combination of upper and lower motor neuron signs and symptoms. The most recent studies suggest that up to 50% of Amyotrophic Lateral Sclerosis patients demonstrate mild to moderate cognitive disturbance. Impaired social cognition, including a deficit in the recognition of facial emotions and the identification of vocal prosody, is recognized as a part of the cognitive phenotype of Amyotrophic Lateral Sclerosis, with crucial implications for patients' and caregivers' training. However, studies remain scarce and the data acquired must be supported. The evolution of these manifestations during the disease is still poorly understood.

In this study the investigators aim to assess the social cognition capacities of patients with Amyotrophic Lateral Sclerosis compared to healthy matched control subjects.

Inclusion Criteria:

Patient Amyotrophic Lateral Sclerosis :

• Education of at least 7 years
• Native language: French
• Patients Amyotrophic Lateral Sclerosis
• Signature of informed consent to participate in the study
• Accompanied patient

Control subject :

• People without any pathology
• Education of at least 7 years
• Native language: French
• Signature of informed consent to participate in the study

Exclusion Criteria:

Patient Amyotrophic Lateral Sclerosis and control subject :

• Simultaneous participation in another interventional protocol with experimental treatment
• Inability to perform cognitive study tests
• Pregnant, lactating or parturient women
• Persons deprived of their liberty by administrative or judicial decision
• Persons under psychiatric care under duress
• Persons subject to legal protection measures
• Persons out of state to express their consent
• People not affiliated or not beneficiaries of a social security scheme
• History likely to disturb cognition

Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared later upon request (e.g., the CRF to allow a collaborator to select the data to which they wish to have access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the MIVAR investigator, based on a protocol provided by the applicant, after verification of obtaining regulatory authorizations, including the favorable opinion of an ethics committee.

The data will be shared after signing a negotiated data transfer contract (data access agreement), for the duration indicated in the contract.

The data will be made available via secure transfer (sharing platform validated by Angers CHU: BlueFiles or Oodrive).